HIV and viral hepatitis coinfections: advances and challenges, Gut, vol.61, issue.Suppl 1, pp.47-58 ,
DOI : 10.1136/gutjnl-2012-302062
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France, HIV Medicine, vol.11, issue.5, pp.308-325, 2010. ,
DOI : 10.1111/j.1468-1293.2009.00780.x
Tenofovir Effect on the Kidneys of HIV-Infected Patients: A Double-Edged Sword?, Journal of the American Society of Nephrology, vol.24, issue.10, pp.1519-1546, 2013. ,
DOI : 10.1681/ASN.2012080857
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons, Current Opinion in HIV and AIDS, vol.9, issue.1, pp.41-48 ,
DOI : 10.1097/COH.0000000000000023
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons, AIDS, vol.28, issue.2, pp.187-99, 2014. ,
DOI : 10.1097/QAD.0000000000000042
Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes, Liver International, vol.36, issue.Suppl. 1, pp.1153-63, 2014. ,
DOI : 10.1111/liv.12549
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology, Feb, vol.59, issue.2, pp.434-476, 2014. ,
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, The Lancet, vol.381, issue.9865, pp.468-75, 2013. ,
DOI : 10.1016/S0140-6736(12)61425-1
Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients, Alimentary Pharmacology & Therapeutics, vol.64, issue.Suppl 1 ,
DOI : 10.1111/apt.13659
Noninvasive markers of liver fibrosis remain stable in the majority of hepatitis B virus and human immunodeficiency virus co-infected patients undergoing tenofovir-containing antiretroviral therapy, Hepatology, vol.62, p.1026, 2015. ,
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5??years, Hepatology International, vol.59, issue.2, pp.243-50 ,
DOI : 10.1007/s12072-015-9614-4
Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure, The Journal of Infectious Diseases, vol.210, issue.3 ,
DOI : 10.1093/infdis/jiu107
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091582
Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir) in HIV-1/Hepatitis B Coinfected Adults, J Acquir Immune Defic Syndr, p.1069 ,
Tenofovir and bone health, Current Opinion in HIV and AIDS, vol.11, issue.3, 2016. ,
DOI : 10.1097/COH.0000000000000248
Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection, Journal of Viral Hepatitis, vol.154, issue.11, pp.936-983, 2015. ,
DOI : 10.1111/jvh.12398
? Significance between treatment groups determined using Kruskal- Wallis test for continuous variables and Pearson ?² test or Fisher's exact test for categorical variables. (n=237) P ? Demographics at inclusion Sex ratio, males/females (% males, pp.56-71 ,
** Number (%) ? Significance between treatment groups determined using Kruskal-Wallis test for continuous variables and Pearson ?² test or Fisher's exact test for categorical variables ,